Tudur Smith News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Tudur Smith. Real-time updates on events, politics, business and more.

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

April 25, 2023

FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 -amyotrophic lateral sclerosis is a devastating, uniformly... | April 25, 2023

Puerto Rico United Kingdom United States Christophera Viehbacher Timothym Miller Tudur Smith

Source: marketscreener.com

Biogen Inc.: FDA Grants Accelerated Approval for QALSODY (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

April 25, 2023

FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly

Puerto Rico United Kingdom United States Timothym Miller Jean Swidler Tudur Smith

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Tudur Smith News Today

FDA Grants Accelerated Approval for QALSODY&#x2122;&#xA0;(tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

Biogen Inc.: FDA Grants Accelerated Approval for QALSODY (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

Explore More Categories

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS